Hormone Therapy
Articles tagged with Hormone Therapy
Slowly ticking breast cancer cells offer new clues to late relapse
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
NIH-funded study suggests that testosterone suppresses brain tumor growth in males
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
Hormone patches effective for locally advanced prostate cancer
A large clinical trial led by UCL researchers has shown that hormone patches are as effective as injections in controlling locally advanced prostate cancer. The patches cause fewer side effects, including hot flushes and breast tissue swelling, while improving quality of life for men with the condition.
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive
A new analysis shows elinzanetant effectively relieves moderate-to-severe vasomotor symptoms (VMS) associated with endocrine therapy, regardless of the type of hormone treatment. The drug reduces VMS frequency and severity by blocking a protein that triggers these symptoms.
Upcoming Alliance webinar highlights latest cancer treatment advances
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA study finds
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
Menopausal hormone therapy not linked to increased risk of death
A large Danish study found that menopausal hormone therapy is not associated with an increased risk of death in women with moderate to severe symptoms and no contraindications. The study also showed a significant survival benefit for women who had undergone bilateral oophorectomy after using hormone therapy.
Blocking pain at the source: Hormone therapy rewires nerve signals in aging spines
Researchers found that hormone treatment reduces abnormal nerve invasion and improves chronic back pain by limiting nerve growth inside damaged spinal tissue. The study suggests that parathyroid hormone can reverse the process by activating natural signals.
‘Masculinity crisis’: Influencers on social media promote low testosterone to young men, study finds
A new study found that social media influencers are promoting unproven claims about low testosterone in young men, framing common experiences as hormonal deficiencies. The content is linked to the manosphere, encouraging hyper-masculine ideals and positioning testosterone as a way for men to reclaim power and status.
Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Hidden virus linked to hip bone collapse, offering hope for true prevention of osteonecrosis
A new clinical study identifies localized reactivation of human cytomegalovirus inside the femoral head as a potential cause of osteonecrosis. The findings suggest that antiviral prevention strategies may be effective in blocking disease progression.
Alliance trial reveals gene variant may affect prostate cancer drug efficacy
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
Menopause hormone therapy does not appear to impact dementia risk
A comprehensive review of prior research found no evidence that menopause hormone therapy increases or decreases dementia risk in post-menopausal women. The study included data from over 1 million participants and analyzed the impact on mild cognitive impairment and Alzheimer's disease, with no significant association found.
Combined oral contraceptive use among people with migraine with aura persists, despite cautions
A new study found that a sizable minority of people with migraine with aura still receive estrogen-containing birth control pills and hormone therapy, despite treatment contraindications. The study highlights the need for updated research on stroke risks associated with these medications among people with this type of migraine.
Menopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations
A matched prospective analysis of 676 women found that menopausal hormone therapy was not associated with an increased risk of breast cancer in those with BRCA mutations. This suggests a personalized approach to menopause management for these women, balancing the risks and benefits of MHT use.
Study suggests many men may not need long-term hormone therapy for prostate cancer
A study published in JAMA Oncology found that shorter courses of androgen deprivation therapy can effectively control prostate cancer without increasing risks. The ideal duration of ADT depends on cancer risk, allowing for more personalized treatment plans.
Updated labeling for menopausal hormone therapy
The FDA has revised the labeling for menopausal hormone therapy based on current evidence, which may affect patient safety and treatment options. The updated guidelines aim to provide more accurate information for healthcare providers and patients.
Hormone therapy alters body proteins to match gender identity
A new study found that hormone therapy can alter sex-specific blood proteins in transgender women, resembling those of cisgender women. The therapy may reduce the risk of heart disease and increase the risk of allergic and autoimmune diseases.
New Alliance trial aims to improve outcomes in metastatic prostate cancer
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
Brazilian researchers warn that healthcare for transgender people is under threat
New Brazilian regulations restrict hormone therapy and research for transgender youth, potentially increasing depression, social isolation, and suicide. Experts question the scientific basis and ethics of these rules, calling for evidence-based care and open discussion.
Researchers sound warning about women with type 2 diabetes taking oral HRT
Women with type 2 diabetes taking oral hormone replacement therapy are at a higher risk of developing pulmonary embolism and heart disease. Transdermal HRT, on the other hand, appears safer, reducing cardiovascular risk by up to 25%.
Addition of progesterone leads to increased breast growth for those taking gender-affirming hormones
The addition of progesterone to gender-affirming hormone therapy leads to increased breast growth for transgender individuals. Progesterone, a key female sex hormone, was found to be safe and effective when added to oestradiol, with participants experiencing up to a 37% increase in breast volume.
Pre-eclampsia increases risk of heart disease
A study by Minttu Venetkoski found that pre-eclampsia increases the risk of ischaemic heart disease and stroke by approximately 1.5-fold. Women with a history of pre-eclampsia are advised to inform their doctors, as this can help mitigate cardiovascular risks during menopause.
Pediatric investigation’s study reveals Cornelia de Lange syndrome characteristics in the Chinese population
A study by Professor Chunxiu Gong's team identified the clinical presentation of Cornelia de Lange syndrome (CdLS) and genetic alterations in Chinese pediatric patients. The researchers found that 12 patients presented with classic CdLS, while others showed global developmental delays and growth retardation.
Hormone therapy type matters for memory performance after menopause
A study found that hormone therapy type impacts memory performance in postmenopausal women, with transdermal estradiol patches enhancing episodic memory and pill form improving prospective memory. The type of hormone therapy taken during and after menopause may influence cognitive performance differently across various types of memory.
Big data begins to crack the cold case of endometriosis
A study using anonymized patient records from UC health centers found over 600 correlations between endometriosis and other conditions, including infertility, autoimmune disease, and certain cancers. The research supports the growing understanding of endometriosis as a multi-system disorder.
Breast cancer risk in younger women may be influenced by hormone therapy
A new study by the NIH found that hormone therapy may alter breast cancer risk in women under 55. Women treated with unopposed estrogen hormone therapy were less likely to develop breast cancer, while those using estrogen plus progestin hormone therapy were more likely to develop the disease.
New review highlights bone health risks linked to modern cancer treatments
A comprehensive review highlights the impact of anti-cancer treatments on bone health, increasing the risk of fractures and bone fragility. The International Osteoporosis Foundation advocates for a multidisciplinary approach to early screening and proactive bone-protective strategies.
Patients are opting in for 10 years of breast cancer treatment
A new study of 591 women with early-stage breast cancer found that nearly two-thirds opted for continued endocrine therapy beyond the initial five years. Patients with higher-risk stage 2 disease were more likely to continue treatment, highlighting potential benefits in extending hormone-based therapy for these patients.
City of Hope scientists present leading-edge research at American Association for Cancer Research (AACR) Annual Meeting
Researchers with City of Hope will present innovative clinical trial results, breakthrough diagnostic techniques, and advances in treatment options at the AACR Annual Meeting. Highlights include a phase 3 clinical trial showing promising results for novel immunotherapy against nasopharyngeal carcinoma.
Study: potential therapy for uncontrolled hypertension
Researchers identified a potential new treatment, lorundrostat, which reduced systolic blood pressure in individuals with uncontrolled or treatment-resistant hypertension. The study found a significant 15-point reduction in systolic blood pressure compared to placebo.
World Hormone Day 2025 – global endocrine community unites to raise public awareness of the small steps everyone can take towards good hormone health
The European Society of Endocrinology and the European Hormone and Metabolism Foundation launch a global campaign to raise awareness about hormone balance and its impact on chronic diseases. Small steps can make a big difference in improving hormone health.
Can hormone therapy improve heart health in menopausal women?
A new analysis found that oral hormone therapy can lower levels of lipoprotein(a), a genetic risk factor associated with higher risk of heart attack and stroke. Hormone therapy also improved biomarkers of cardiovascular health, including cholesterol levels.
Researchers may have solved decades-old mystery behind benzodiazepine side effects
A research team has identified a key protein suspected to be involved in benzodiazepine-related inflammation, which could inform strategies to improve benzodiazepine drug design and treat inflammation-related conditions. The findings may lead to new treatments for diseases such as Alzheimer's, arthritis, and multiple sclerosis.
New research on common breast cancer that is resistant to hormone therapies
Researchers have developed a new approach to overcome treatment resistance in estrogen receptor-positive (ER+) breast cancer. Dual aromatase-steroid sulfatase inhibitors (DASIs) show promise in effectively blocking both enzymes involved in oestrogen production, potentially reducing tumour growth.
Menstrual cycle may contribute to sickle cell disease pain crises
Researchers have discovered a significant increase in inflammation and C-reactive protein levels in female patients with sickle cell disease during the follicular phase of their menstrual cycle. This finding may help identify potential targets for managing pain crises, particularly when combined with hormonal contraceptives.
Three out of ten breast cancers are detected between screenings
A new study found that interval cancers, which are detected between two screening sessions, account for 30% of all breast cancers. Women with high breast density, hormone therapy, and a family history of breast cancer are at increased risk. More frequent or improved screening methods could significantly improve early detection rates.
Study focuses on resistance to androgen receptor-targeted therapy in advanced prostate cancer
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
Open-label placebos improve premenstrual syndrome
A study found that open-label placebos alleviated symptoms of premenstrual syndrome (PMS) in women, with effects greatest when provided with additional information. The placebo effect played a significant role, accompanied by improved self-efficacy and reduced symptom intensity.
Why some breast cancer treatments stop working
A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.
The emerging role of flavonoids in the treatment of type 2 diabetes mellitus: regulating the enteroendocrine system
Research suggests flavonoids improve insulin sensitivity, enhance β-cell function, modulate the gut microbiota, inhibit gluconeogenesis, and regulate enteroendocrine hormones in type 2 diabetes management. Flavonoid-specific effects on GLP-1, GIP, PYY, and CCK secretion contribute to improved glycemic control.
Potential treatment for chronic kidney disease in dogs revealed
A new study suggests that paricalcitol may help manage chronic kidney disease (CKD) in dogs by reducing renal secondary hyperparathyroidism and proteinuria. The treatment showed promise in stabilizing proteinuria, but raised questions about potential long-term effects on CKD progression.
Gender-affirming hormone therapy and depressive symptoms among transgender adults
A longitudinal observational cohort study found that gender-affirming hormone therapy was associated with lower rates of moderate-to-severe depressive symptoms. The study highlights the importance of gender-affirming primary care models for transgender, nonbinary, and gender diverse patients.
Among older women, hormone therapy linked to tau accumulation, a hallmark of Alzheimer’s disease
A study by Mass General Brigham researchers found that women over 70 who took hormone therapy had faster tau accumulation than those who didn't. This increase was seen in specific brain regions vulnerable to Alzheimer's disease. The findings suggest delaying hormone therapy may lead to worse Alzheimer's outcomes.
Menopause symptoms associated with future memory and neuropsychiatric problems
A study of nearly 900 postmenopausal women found an association between perimenopausal symptom burden and later cognitive function and behavioral impairment. Women with higher menopausal symptom burdens were more likely to experience poorer cognitive function and mild behavioral impairments, both markers of dementia.
MD Anderson Research Highlights for February 26, 2025
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
NUS Medicine pioneers ground-breaking technique to deliver drugs directly to the brain
Scientists at NUS Medicine have developed a novel approach using nasal bacteria to deliver therapeutic molecules directly to the brain, reducing appetite and improving glucose metabolism in preclinical studies. The engineered bacteria leverage the olfactory mucosa's unique properties to deliver medication with enhanced bioavailability.
Simple treatment can save lives for men with a common chromosomal disorder
A Danish study reveals that testosterone treatment can nearly halve the mortality rate among men with Klinefelter syndrome, reducing cardiovascular disease risk and increasing life expectancy. The treatment also improves quality of life and may have positive effects on metabolism, muscle mass, and bone health.
MD Anderson Research Highlights for February 10, 2025
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
Communication between body muscle and the brain influences fertility, study finds
Researchers at McGill University found that a protein produced in muscles helps manage the release of follicle-stimulating hormone (FSH), which promotes egg maturation. Lowering myostatin levels delayed puberty and reduced fertility, while restoring it boosted FSH levels.
A protein at the heart of heart disease
ApoB100 protein structure revealed for the first time, allowing for more precise testing and treatment of high cholesterol and heart disease. The discovery may lead to new drugs targeting LDL particles, reducing side effects of statin drugs.
Major uncertainties remain about impact of treatment for gender related distress
Two pooled data analyses suggest that puberty blockers and gender-affirming hormone therapy have no conclusive evidence on their effectiveness or impact on mental and physical health. The findings echo the Hilary Cass review, concluding that the evidence is wholly inadequate to gauge the effectiveness of these treatments.
Super enzyme that regulates testosterone levels in males discovered in ‘crazy’ bird species
Researchers at Simon Fraser University and the Max Planck Institute have identified a single gene controlling testosterone levels in three male morphs of shore birds, also applicable to vertebrates including humans. This super enzyme (HSD17B2) rapidly breaks down testosterone, producing diverse mating behaviors.
HER2-low breast cancer: Genomic insights and evolving treatment paradigms
Researchers explore HER2-low breast cancer, a new clinical subtype that benefits from novel treatments and personalized care. Current testing methods are not always accurate, calling for better detection methods to correctly identify patients who can benefit from these new therapies.
Arginase-II deficiency slows skeletal muscle aging in mice
Researchers discovered that removing arginase-II gene can slow down muscle aging in mice, leading to improved muscle health and reduced inflammation. This finding suggests targeting the Arg-II gene could help maintain muscle strength and mobility in older adults.
Florescent probes illuminate cholesterol and Alzheimer’s research
A new study demonstrates how fluorescent cholesterol probes can visualize cholesterol in live cells, revealing its role in amyloid plaque formation and cellular signaling. The novel probes have the potential to enhance our understanding of how cholesterol imbalances contribute to neurodegenerative disorders.
Study identifies mechanism underlying increased osteoarthritis risk in postmenopausal females
A new study identifies the molecular mechanisms underlying increased osteoarthritis risk in postmenopausal females, revealing that menopause-induced changes in sex hormone levels contribute to joint degeneration. Restoring these hormones may protect against cartilage degeneration, paving the way for novel treatments.